Bench Side Story continues with Dr Michael Collins, a kidney transplant specialist at Royal Adelaide Hospital in South Australia.
He is the Principal Investigator of a trial called the BEST Fluids trial, which has recently been completed and showed which was the best treatment in terms of intravenous fluids to use for kidney transplant recipients.
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
-
Vaccine effectiveness against infections triggering autoimmune disease
Dr Deborah Burnett is a Scientia Senior Lecturer and Laboratory Head at UNSW, where she leads a multidisciplinary research program spanning mechanistic immunology and translational vaccinology. Her work focuses on understanding how immune responses can protect against challenging infectious threats, including bacterial infections and infections associated with autoimmune disease.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
